-
Comprehensive Analysis of Orelabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Phase 1/2 Study
Mantle cell lymphoma (MCL) represents a distinct subtype of B-cell non-Hodgkin lymphoma, characterized by its aggressive nature and poor prognosis, particularly in the relapsed or refractory (r/r) setting. The advent…
-
Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study
Marginal zone lymphoma (MZL) is a subtype of non-Hodgkin lymphoma characterized by a slow progression. It originates from B cells in the marginal zone of lymphoid tissues and is associated…
-
Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin lymphoma represents a unique therapeutic challenge, particularly for those with relapsed or refractory disease after first-line therapies. Despite advances in treatment, the prognosis for this subgroup remains suboptimal. Anti-programmed…
-
Unlocking the Cure: A Groundbreaking Study on ENKTCL Treatment Success Rates and Implications
The research on Extranodal nasal-type natural killer/T-cell lymphoma (ENKTCL) has seen significant advancements in recent years, with improved treatment modalities enhancing patient survival rates. The study titled “Evidence of Cure…
-
Dr. Myron Schwartz: The Development and Prospects of Multidisciplinary Comprehensive Treatment of Liver Cancer
Primary liver cancer is one of the common malignant tumors worldwide. With the development of modern biomedical technology, clinical surgical techniques, and minimally invasive treatment techniques, the surgical treatment level of liver cancer has made significant progress. At the recently concluded global academic event in the field of liver cancer – the 17th Annual Meeting…
-
Dr. Masatoshi Kudo: “T+A” Shows Significant Clinical Benefits in Intermediate-Stage HCC Patients Unsuitable for TACE Treatment
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor posing a significant threat to human health with considerable heterogeneity. Specifically, intermediate-stage HCC spans a range from liver function reserve ChHepatology Digest-Pugh A grade (5 points) to B grade (9 points), tumor sizes from 5 cm to >10 cm, and the number of nodules from 4 to…
-
ILCA 2023 | Exploration of Immunotherapy as Neoadjuvant Treatment in Reducing Postoperative Recurrence of HCC
Immune checkpoint inhibitors (ICIs) have been widely used in the clinical treatment of patients with advanced hepatocellular carcinoma (HCC), significantly improving their survival. While early-stage HCC can be cured with hepatectomy, up to 70% of patients may experience tumor recurrence within two years post-surgery. Therefore, the feasibility of perioperative ICI use to effectively inhibit tumor…
-
ILCA 2023 | Liver Frailty Index as an Independent Predictor of Mortality in Advanced HCC Patients Undergoing Systemic Treatment
Systemic treatment can extend the overall survival of patients with advanced hepatocellular carcinoma (HCC). However, results vary among individuals, and the predictive factors for survival rates in advanced HCC patients are still unclear. Previous studies have shown that the patient’s frailty index is related to adverse outcomes in liver cirrhosis and liver transplant recipients. It…
Connecting Medical Expertise through Media